Clive Mulatero

Leeds, ENG, GB 
Leeds, ENG, GB 

Overview

Clive Mulatero practices practicing medicine in Leeds, United Kingdom.

His clinical expertise encompasses Melanoma, Lung Cancer, Small Cell Lung Cancer (SCLC), and Non-Small Cell Lung Cancer (NSCLC).

He is actively involved in clinical research, co-authoring 12 peer reviewed articles and participating in 3 clinical trials.

Gender

Male

Locations

Leeds, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

National Lung Matrix Trial: Multi-drug, Genetic Marker-directed, Non-comparative, Multi-centre, Multi-arm Phase II Trial in Non-small Cell Lung Cancer
National Lung Matrix Trial: Multi-drug, Genetic Marker-directed, Non-comparative, Multi-centre, Multi-arm Phase II Trial in Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: April 28, 2026
Intervention Type: Drug
Study Drugs: AZD4547, Vistusertib, Palbociclib, Crizotinib, Selumetinib, Docetaxel, AZD5363, Osimertinib, Durvalumab, Sitravatinib, AZD6738
Study Phase: Phase 2
A Phase II Randomised, Open-label Study of Gemcitabine/Carboplatin First-line Chemotherapy in Combination With or Without the Antisense Oligonucleotide Apatorsen (OGX-427) in Advanced Squamous Cell Lung Cancers
A Phase II Randomised, Open-label Study of Gemcitabine/Carboplatin First-line Chemotherapy in Combination With or Without the Antisense Oligonucleotide Apatorsen (OGX-427) in Advanced Squamous Cell Lung Cancers
Enrollment Status: Unknown
Publish Date: August 22, 2017
Intervention Type: Drug
Study Drugs: Apatorsen, Gemcitabine, Carboplatin
Study Phase: Phase 2
A Phase I/II Trial of SCIB1, a DNA Immunotherapy, in the Treatment of Patients With Malignant Melanoma
A Phase I/II Trial of SCIB1, a DNA Immunotherapy, in the Treatment of Patients With Malignant Melanoma
Enrollment Status: Terminated
Publish Date: August 21, 2017
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trials

12 Total Publications

Long term efficacy of first-line afatinib and the clinical utility of ctDNA monitoring in patients with suspected or confirmed EGFR mutant non-small cell lung cancer who were unsuitable for chemotherapy.
Long term efficacy of first-line afatinib and the clinical utility of ctDNA monitoring in patients with suspected or confirmed EGFR mutant non-small cell lung cancer who were unsuitable for chemotherapy.
Journal: British journal of cancer
Published: June 21, 2024

Frequently Asked Questions about Clive Mulatero

Is Clive Mulatero a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Clive Mulatero is classified as an Experienced expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Clive Mulatero participate in research or clinical trials?

Yes. Clive Mulatero has published 12 articles and abstracts on conditions like Melanoma. You can view a list of Clive Mulatero's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Mulatero's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile